Neurizon Therapeutics (ASX:NUZ), a clinical-stage biotech focused on neurodegenerative diseases, has provided an update on its lead investigational therapy for Amyotrophic Lateral Sclerosis, NUZ-001.
The company said NUZ-001, designed to inhibit TDP-43 aggregation—a key driver of motor neuron degeneration—has progressed to the next operational phases of the HEALEY ALS platform trial, including Institutional Review Board submissions and clinical site activation, with patient enrollment expected early this year.
On the regulatory front, Neurizon disclosed that the US FDA has declined its current request for Fast Track Designation, while providing guidance on additional clinical data needed to support a future application.
The FDA reaffirmed ALS as a serious condition with unmet medical needs, offering Neurizon a clear pathway for regulatory advancement.
These developments follow the company's recent announcement of secured funding to complete its pivotal Phase 2/3 registration-adaptive trial, which aims to accelerate the evaluation of ALS therapies under a multicenter, double-blind, placebo-controlled framework.